Nazione: Australia
Lingua: inglese
Fonte: Department of Health (Therapeutic Goods Administration)
cisplatin, Quantity: 1 mg/mL
Hospira Australia Pty Ltd
Cisplatin
Injection, intravenous infusion
Excipient Ingredients: mannitol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide
Intravenous Infusion
1 x 50mL vial
Medicine Listed (Export Only)
(S1) This Schedule is intentionally blank
Cisplatin is indicated for the treatment of: Metastatic carcinoma of non-seminoma germinale cells, Advanced and refractory carcinoma of the ovary, Advanced and refractory carcinoma of the bladder, epidemiological carcinoma of the head and the neck.
Visual Identification: a clear, colourless to pale yellow solution free from visible particulates; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 2 Years; Container Temperature: Store between 15-25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2009-03-10